TY - JOUR T1 - Analysis of drug resistance of extended-spectrum beta-lactamases-producing <em>Escherichia coli</em> and <em>Klebsiella pneumoniae</em> in children with urinary tract infection JF - Saudi Medical Journal JO - Saudi Med J SP - 1111 LP - 1115 DO - 10.15537/smj.2019.11.24547 VL - 40 IS - 11 AU - Lu Keshi AU - Xiao Weiwei AU - Li Shoulin AU - Liu Xiaodong AU - Wang Hao AU - Jiang Junhai AU - Wang Xiangwei AU - Wang Rui AU - Zhu Pei Y1 - 2019/11/01 UR - http://smj.org.sa/content/40/11/1111.abstract N2 - Objectives: To investigate the drug resistance of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K.pneumoniae) in children with urinary tract infection (UTI) and to provide the rationale for clinical use of antibiotics.Methods: This is a retrospective analysis of drug susceptibility in children with E. coli or K. pneumoniae-positive urine culture between August 2013 and August 2017, Shenzhen Children’s Hospital, Shenzhen, China. Drug resistance was statistically assessed using Fisher exact test and χ2 test.Results: A total of 698 cases of E. coli, 426 of which were confirmed ESBL-producing strains, and 217 cases of K. pneumoniae, including 111 ESBL-producing strains, were detected, and the difference in proportion of positive ESBL-producing strains (61.03% versus 51.15%) was statistically significant (p=0.010). The average drug resistance rates of E. coli and K. pneumoniae to piperacillin/tazobactam, meropenem, ertapenem, imipenem, and amikacin were &lt;15%. The average resistance rates of ESBL-producing E. coli and K. pneumoniae to cefpodoxime, cefixime, cefazolin, and ceftriaxone was &gt;98%, while average resistance rates for non-ESBL-producing bacteria to the above 4 drugs was &lt;20%.Conclusion: In southern China, the proportion of ESBL-producing strains and the drug resistance rates of E. coli and K. pneumoniae in UTI in children was high, but their resistance rates to carbapenems and β-lactamase inhibitor complexes containing tazobactam were low. Carbapenems are the most effective antibacterial drugs for the treatment of ESBL-producing bacteria. ER -